Trends in the use of typical and atypical antipsychotics in children and adolescents.

OBJECTIVE To estimate prevalence rates of antipsychotic use in children and adolescents from 1996 to 2001 in three state Medicaid programs (midwestern [MM], southern [SM], and western [WM]) and one private managed care organization (MCO). METHOD Prescription claims were used to evaluate antipsychotic prevalence, defined as the number of children and adolescents up to the age of 19 years with at least one prescription claim for an antipsychotic per 1,000 enrolled youths. RESULTS From 1996 to 2001, the prevalence of total antipsychotic use increased in each program (MM: 4.7 to 14.3 per 1,000; SM: 6.3 to 15.5; WM: 4.5 to 6.9; and MCO: 1.5 to 3.4). Typical antipsychotic use decreased (MM: 3.7 to 2.0 per 1,000; SM: 4.6 to 1.5; WM: 4.4 to 1.3; and MCO: 1.2 to 0.9), while atypical antipsychotic use dramatically increased (MM: 1.4 to 13.1 per 1,000; SM: 2.5 to 14.9; WM: 0.3 to 6.2; and MCO: 0.4 to 2.7). CONCLUSIONS The increased prevalence of antipsychotic use in children and adolescents from 1996 to 2001 was attributed to increased use of atypical antipsychotics. Given the limited data with atypical antipsychotics in youths, this emphasizes the need for additional studies of these agents and other treatment modalities in this population.

[1]  R. Findling,et al.  Atypical antipsychotics in the treatment of children and adolescents: clinical applications. , 2004, The Journal of clinical psychiatry.

[2]  M. DelBello,et al.  Phenomenology and epidemiology of childhood psychiatric disorders that may necessitate treatment with atypical antipsychotics. , 2004, The Journal of clinical psychiatry.

[3]  Jeanne S. Ringel,et al.  Geographic disparities in children's mental health care. , 2003, Pediatrics.

[4]  Robyn Tamblyn,et al.  Physician and Practice Characteristics Associated with the Early Utilization of New Prescription Drugs , 2003, Medical care.

[5]  E. Youngstrom,et al.  A prospective, open-label trial of olanzapine in adolescents with schizophrenia. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  M. Crismon,et al.  Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. , 2003, Journal of the American Academy of Child and Adolescent Psychiatry.

[7]  Andrés Martin,et al.  Datapoints: use of multiple psychotropic drugs by Medicaid-insured and privately insured children. , 2002, Psychiatric services.

[8]  S. Strakowski,et al.  A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[9]  M. Aman,et al.  Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[10]  R. Findling,et al.  Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. , 2002, The American journal of psychiatry.

[11]  C. McDougle,et al.  Risperidone in children with autism and serious behavioral problems. , 2002, The New England journal of medicine.

[12]  S. Marcus,et al.  Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. , 2002, Psychiatric services.

[13]  J. Lewis,et al.  A study of quetiapine: efficacy and tolerability in psychotic adolescents. , 2001, Journal of child and adolescent psychopharmacology.

[14]  R. Owen,et al.  Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. , 2001, Psychiatric services.

[15]  M. Olfson,et al.  Prescription of psychotropic medications to youths in office-based practice. , 2001, Psychiatric services.

[16]  J. Buitelaar,et al.  A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. , 2001, The Journal of clinical psychiatry.

[17]  B. Martin,et al.  Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts , 2001, Schizophrenia Research.

[18]  S. Schulz,et al.  Antipsychotic medications in children and adolescents. , 2001, The Journal of clinical psychiatry.

[19]  J. Swanson,et al.  Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): Implications and Applications for Primary Care Providers , 2001, Journal of developmental and behavioral pediatrics : JDBP.

[20]  M. Schluchter,et al.  A double-blind pilot study of risperidone in the treatment of conduct disorder. , 2000, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  P. Marken,et al.  Atypical antipsychotic agents: a critical review. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  J. Rohrer,et al.  Substitution of Psychiatric Care by Primary Care Physicians: Impact of the Iowa Medicaid Managed Mental Health Care Plan , 1999, Administration and Policy in Mental Health and Mental Health Services Research.

[23]  R. Malone,et al.  Novel antipsychotic medications in the treatment of children and adolescents. , 1999, Psychiatric services.

[24]  J. Rapoport,et al.  Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. , 1998 .

[25]  J. Gorman,et al.  Risperidone in adolescents with schizophrenia: an open pilot study. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  J. Asarnow,et al.  Childhood-Onset Schizophrenia , 1994 .

[27]  M. Olfson,et al.  Pharmacotherapy in outpatient psychiatric practice. , 1994, The American journal of psychiatry.

[28]  J. Archer,et al.  Aggressive behaviour of children aged 6-11: gender differences and their magnitude. , 1988, The British journal of social psychology.

[29]  C. Sheppard,et al.  Comparative Survey of Psychiatrists' Prescription Preferences , 1975 .

[30]  L. Magder,et al.  Psychotropic practice patterns for youth: a 10-year perspective. , 2003, Archives of pediatrics & adolescent medicine.

[31]  M. Jellinek.  Mirror, mirror on the wall: are we prescribing the right psychotropic medications to the right children using the right treatment plan? , 2003, Archives of pediatrics & adolescent medicine.

[32]  M. Crismon,et al.  Trends in antipsychotic use in a Texas medicaid population of children and adolescents: 1996 to 2000. , 2002, Journal of child and adolescent psychopharmacology.

[33]  M. Tohen,et al.  A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. , 2001, Journal of child and adolescent psychopharmacology.

[34]  Marc van Bellinghen,et al.  Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. , 2001 .

[35]  H. Schreier.  Risperidone for young children with mood disorders and aggressive behavior. , 1998, Journal of child and adolescent psychopharmacology.

[36]  C. Hoven,et al.  Children's access to mental health care: does insurance matter? , 1997, Health affairs.